Workflow
Doximity(DOCS)
icon
搜索文档
Doximity(DOCS) - 2024 Q2 - Earnings Call Transcript
2023-11-10 12:56
业绩总结 - Doximity在2024财年第二季度实现了1.14亿美元的收入,超出了指导范围的高端4%[1] - 调整后的EBITDA利润率为48%,达到了5400万美元,比指导范围的高端高出20%[2] - Doximity的独特活跃用户数量在上一季度创下历史新高,年同比增长了两位数百分比[3] - Doximity的AI算法每月阅读超过50万篇文章,为医生提供个性化新闻摘要[4] 未来展望 - Doximity将年度收入指导范围的中点提高了600万美元,达到11%的年度增长率[5] - Doximity将EBITDA指导范围的中点提高了6%,达到2.13亿美元,EBITDA利润率为46%[6] - Doximity撤回了5年增长目标,但仍然期望在2028年成为10亿美元公司[7] 新产品和新技术研发 - Doximity推出了新的医生隐私服务产品DocDefender.com,旨在保护医生家庭的个人信息[8] - Doximity在过去一季度取得了巨大进展,推出了强大的自助式制药客户门户网站[9] 市场扩张和并购 - Doximity计划在明年初向所有制药客户开放客户门户网站,并在明年夏季的升级季节增加更多功能[10] 其他新策略和有价值的信息 - 公司撤回了2028年的营收和65规则目标,但重申了长期运营模型指导[11] - 公司目前拥有51个百万美元以上的客户,同比增长28%[12]
Doximity(DOCS) - 2024 Q2 - Quarterly Report
2023-11-09 00:00
财务数据 - 公司截至2023年9月30日收入为2.221亿美元,同比增长15%[55] - 公司2023年9月30日净收入为3060万美元,调整后的EBITDA为5420万美元[55] - 公司2023年第三季度净利润为30,602千美元,较2022年同期增长16%[58] - 公司2023年第三季度调整后的EBITDA为54,180千美元,较2022年同期增长18%[58] - 公司2023年第三季度营收为113,612千美元,较2022年同期增长11%[58] - 公司2023年第三季度自由现金流为67,255千美元,较2022年同期下降16%[59] 客户数据 - 公司客户中收入超过10万美元的数量为290,较2022年增长了9个客户[56] 产品和技术 - 公司营收主要来自市场解决方案和招聘解决方案[60] - 公司研发支出预计将随着平台和产品的扩张而增加[66] 财务策略 - 公司相信现有的现金及市场证券足以支持至少未来12个月的营运资金和资本支出需求[73] - 公司在2023年前6个月的经营活动中提供了7,009.8万美元的现金[75]
Doximity(DOCS) - 2024 Q1 - Earnings Call Presentation
2023-08-11 21:08
Interactivity Service Line 05 Awareness PeerPeer Service Line 02 Interactivity Peer Awareness Manufacturer Health System 1 Land Initial Brands or Service Lines 2 Expand to Add'l Brands or Service Lines 3 Expand Number & Type of Modules Utilized Awareness Build brand equity and communicate key messages doximity (1) (2) (3) Proprietary & Confidential Est. Share of Total HCP Marketing Budgets1 >50% 20-50% 5-20% <5% No Revenue Q1 KEY METRICS 13 Adj. EBITDA & Margin1,2 Proprietary 1/3+ IN R&D1 Dr. Nate Gross CSO ...
Doximity(DOCS) - 2024 Q1 - Earnings Call Transcript
2023-08-09 10:54
Elizabeth Anderson Jeffrey Tangney Jeffrey Tangney Got it. Thanks so much. Jailendra Singh Anna Bryson Okay. And then my quick follow-up on upsell. I appreciate all the color around what you're seeing in the market. But just curious to know like whether these upsell, what you're seeing a slowdown, do you see any opportunity that these might come back later part of this year or fiscal year for you guys? Or do you think that's probably pretty much you have enough visibility that probably this is not likely to ...
Doximity(DOCS) - 2024 Q1 - Quarterly Report
2023-08-08 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O ...
Doximity(DOCS) - 2023 Q4 - Annual Report
2023-05-26 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40508 Doximity, Inc. Exact Name of Registrant as Specified in Its Charter) Delaware 27-2485512 (State or Other Jurisdiction of Incorpora ...
Doximity(DOCS) - 2023 Q4 - Earnings Call Transcript
2023-05-17 10:43
To break down the renewal and upsell component further, given the continued macro uncertainty, we are modeling a similar percentage of mid-year upsell to last year, which is about half of our historical rate. Question-and-Answer Session Brian Peterson If you look at the overall industry, I'll know a lot more in a couple of weeks because next week, we're getting together with a few dozen of our top clients to spend a couple of days together talking about the landscape and where we're going together. Brian Pe ...
Doximity(DOCS) - 2023 Q3 - Earnings Call Transcript
2023-02-10 09:47
The next question is from Jessica Tassan with Piper Sandler. Your line is open. Hey folks. Thank you for taking my question. Anna, building on your visibility comments, can you walk us through how you've looked at contracting and get visibility? And maybe give us a bit more of a bridge around the GoGet renewals and already contracted pieces of the revenue for next year? Jeffrey Tangney And we assume that our new products would be as well. And then our new products sold much, much better than we thought. I m ...
Doximity(DOCS) - 2023 Q3 - Quarterly Report
2023-02-09 00:00
财务表现 - 截至2022年12月31日,公司营收为3.081亿美元,同比增长23%[57] - 2022年12月31日,公司净利润为3350万美元,调整后的EBITDA为5550万美元[57] - 截至2022年12月31日,公司拥有超过100,000美元订阅收入的客户数量为2901[59] - 调整后的EBITDA为2022年12月31日的营收的48%[60] - 2022年12月31日,公司的自由现金流为1.27805亿美元[61] - 2022年12月三个月的收入较2021年同期增加了18%[69] - 订阅收入的增长主要来自新增订阅客户和现有客户的扩展[70] - 2022年12月三个月的成本和费用较2021年同期增加了22%[71] 费用支出 - 毛利润是总营收减去总成本,毛利率为总营收的百分比[65] - 研发费用主要包括与工程和产品团队相关的人员费用[66] - 研发支出预计将随着平台和产品的增长而继续增加[67] - 销售和营销支出预计将在绝对金额上增加,并成为最大的支出[67] - 总体运营支出在绝对金额上增加,主要受到研发、销售和营销、以及总务支出的影响[68] - 研发支出在2022年12月三个月和九个月的增长主要受到人员相关成本和股权补偿费用的影响[74] - 销售和营销支出在2022年12月三个月和九个月的增长主要受到人员相关成本和股权补偿费用的影响[74] - 总务支出在2022年12月三个月和九个月的增长主要受到人员相关成本的影响[74] 资金情况 - 公司自成立以来主要通过销售股权证券和客户付款来融资运营[76] - 公司于2022年12月31日的主要流动资金来源是现金及现金等价物和市场证券,总额为8.01亿美元[76] - 公司于2022年9月30日完成了7千万美元的股票回购计划[76] - 公司相信现有的现金及市场证券足以支持未来至少12个月的营运资金和资本支出需求[77] - 2022年前9个月,公司经营活动提供的净现金为1.33亿美元[77] - 2022年前9个月,公司投资活动使用的净现金为4,671.9万美元[77] - 2022年前9个月,公司融资活动提供的净现金为6,259.9万美元[77] 风险管理 - 公司未有任何资产负债表之外的安排[79] - 公司的现金及市场证券主要包括现金、企业票据和债券、资产支持证券、商业票据、存款证书、美国政府和机构债券以及主权债券[84] - 公司的投资受市场风险影响,包括利率变动和通货膨胀[84]
Doximity(DOCS) - 2023 Q2 - Earnings Call Transcript
2022-11-11 13:04
Doximity, Inc. (NYSE:DOCS) Q2 2023 Earnings Conference Call November 10, 2022 17:00 ET Company Participants Perry Gold - Head of Investor Relations Jeff Tangney - Co-Founder & Chief Executive Officer Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder & Chief Scientific Officer Presentation Operator Hello and welcome to Doximity's Fiscal Q2 2023 Earnings Call. I will now pass the call over to Doximity's Head of Investor Relations, Perry Gold, to kick off the call. Perry Gold Thank you operator. He ...